Thomas Equels is the CEO, since early last fall. This change has been happening for awhile. William Mitchell is now the chairman of the board. Mitchell's signature on the June 5 experts letter - representing HEB. When I went to the manufacturing plant open house last fall - Carter was the only top staff person not there. Tightening up the business end might have been a pre-requisite of NIH funding - who knows, that's just a guess.
Market Data 
Markets 
AI
